Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Pneumonia, guideline, pharmacotherapy, 【초록키워드】 coronavirus disease, clinical trial, Chloroquine, Tocilizumab, drugs, Italy, organization, China, Germany, outbreak, Efficacy and safety, Medicines, National, country, effective, highlight, indicated, treatment for COVID-19,
【저자키워드】 COVID-19, SARS-CoV-2, Pneumonia, guideline, pharmacotherapy, 【초록키워드】 coronavirus disease, clinical trial, Chloroquine, Tocilizumab, drugs, Italy, organization, China, Germany, outbreak, Efficacy and safety, Medicines, National, country, effective, highlight, indicated, treatment for COVID-19,